About
Novocure is a commercial-stage oncology company developing a novel, proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers.
TTFields are low-intensity, intermediate-frequency alternating electric fields that disrupt mitosis and cytokinesis. TTFields exert sufficient physical force on charged cellular components to stop normal cell-division processes, specifically the formation of the mitotic spindle from tubulin dimer proteins. TTFields also exert a physical force on other components of the cell during division, causing cell death prior to division.
TTFields therapy is delivered using noninvasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The complete delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries, and more. The portable therapy is designed to be worn continuously throughout the day and night.
Novocure received an FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small cell lung cancer.
Funding history · 2 rounds · $742.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is NovoCure's primary therapeutic focus?
- NovoCure is a commercial-stage oncology company that develops Tumor Treating Fields (TTFields) therapy for the treatment of solid tumor cancers.
- When did NovoCure go public on NASDAQ?
- NovoCure went public on NASDAQ in October 2015, with a valuation of $1.8 billion.
- What was a significant financing event for NovoCure in February 2018?
- In February 2018, NovoCure secured $150 million in debt financing from BioPharma Credit PLC.
- What was the outcome of NovoCure's Phase 3 PANOVA-3 clinical trial for pancreatic cancer?
- In December 2024, NovoCure announced positive topline results from its Phase 3 PANOVA-3 clinical trial, indicating that its TTFields therapy met the primary endpoint for pancreatic cancer.
- What was a key regulatory approval for NovoCure in October 2024?
- In October 2024, the FDA approved NovoCure’s Optune Lua® for the treatment of metastatic non-small cell lung cancer.
- What organizational change did NovoCure announce in September 2024?
- In September 2024, NovoCure announced a planned CEO transition, with Asaf Danziger retiring and CFO Ashley Cordova named as his successor.
- What was the result of NovoCure's METIS Phase 3 clinical trial for brain metastases from non-small cell lung cancer?
- In March 2024, the METIS Phase 3 clinical trial met its primary endpoint, demonstrating a statistically significant extension in time to intracranial progression for patients with brain metastases from non-small cell lung cancer.
- What strategic decision did NovoCure make in November 2023 regarding its operations?
- In November 2023, NovoCure announced a portfolio prioritization and strategic restructuring plan focused on near-term growth drivers and an accelerated path to profitability, which included laying off 200 employees in December 2023.
- What was the outcome of NovoCure's Phase 3 LUNAR clinical trial for metastatic non-small cell lung cancer?
- In June 2023, the LUNAR Phase 3 clinical trial demonstrated a statistically significant and clinically meaningful extension in overall survival for patients with metastatic non-small cell lung cancer after platinum-based therapies.
- What significant regulatory designation did NovoCure receive in September 2021?
- In September 2021, the FDA granted Breakthrough Device Designation to NovoCure's NovoTTF-200T™ System for advanced liver cancer.